Valdilea Veloso, MD, PhD
Valdilea Veloso, MD, PhD, (Faculty Mentor) is Director of the Evandro Chagas Clinical Research Institute. She is co-PI of the FIOCRUZ CTU, ACTG and HPTN co-investigator, and the PI of the IPREX study at FIOCRUZ. She is a team member of two ACTG tuberculosis related protocols: A5221 and A5253. She is a member of the Brazilian Ministry of Health advisory committees for Antiretroviral Therapy and Prevention of Mother-to-Child-Transmission. From 1997 to 2000, she led the Care Division of the National STD/AIDS Program and was the former Director of the Rio de Janeiro State STD/AIDS Program from 2000 to 2003. She has served on the Global Fund for AIDS, Tuberculosis and Malaria Technical Review Panel and as UNAIDS consultant for implementation of HIV/AIDS Care Programs in several developing countries.
Optimization of antiretroviral therapy; Access to ARV therapy in resource-limited settings
Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014 Jun;14(6):459-67.
Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, Guimarães MR, Nunes EP, Lemos AS, Ribeiro SR, Campos DP, Vitoria MA, Veloso VG. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8(4):e59768. doi: 10.1371/journal.pone.0059768.
Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, Siberry G, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moye J, Mofenson LM; NICHD HPTN 040/PACTG 1043 Protocol Team. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012 Jun 21;366(25):2368-79.
Veloso VG, Bastos FI, Portela MC, Grinsztejn B, João EC, Pilotto JH, Araújo AB, Santos BR, Fonseca RC, Kreitchmann R, Derrico M, Friedman RK, Cunha CB, Morgado MG, Saines KN, Bryson YJ. HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil. Rev Saude Publica. 2010 Oct;44(5):803-11.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. PMC3079639
Applications for the 2024-25 Fellowship class are now being accepted. The priority application deadline for the 2024-25 Fellowship class is February 16, 2024.